DeepLife

Yann Abraham, Head of Drug Discovery at DeepLife, will be speaking at the Drug Discovery Innovation Programme (DDIP) Europe 2026 in Basel. The programme brings together drug discovery leaders to discuss how new technologies and approaches are changing the way therapeutic opportunities are identified, prioritised and advanced. Yann will share DeepLife’s perspective on how AI-based digital twins of human cells and causal, cell-type-specific modelling can support stronger decisions in drug discovery, from target identification and prioritisation to indication expansion.  📍 Mövenpick Hotel Basel, Switzerland  📅 29–30 September 2026 Attending DDIP Europe? Connect with Yann to discuss how TwinCell turns complex cellular data into interpretable biological rationale for drug discovery teams. #DrugDiscovery #DDIP2026 #TwinCell #Innovation

DeepLife and Centre Léon Bérard: a clinical atlas collaboration at AACR 2026 DeepLife and Centre Léon Bérard began their scientific partnership in 2023, bringing together clinical and translational oncology expertise with DeepLife's computational biology and AI-ready omics infrastructure. At American Association for Cancer Research 2026, this partnership was reflected in translational work led by our collaborators at Centre Léon Bérard on immunotherapy response in locally advanced and metastatic head and neck squamous cell carcinoma. The study used a single-cell RNA sequencing oral mucosa atlas developed with DeepLife, comprising approximately 660,000 cells from 202 samples and 102 donors. By connecting patient stratification with the biology of the tumor microenvironment, the work shows how clinical expertise and computational biology can support more interpretable disease insight and therapeutic hypotheses. Thank you to Saintigny Pierre, mehdi lamkhioued, Timothée CASINI and the full team at Centre Léon Bérard for this work, and for the opportunity to contribute to it. DeepLife and Centre Léon Bérard are now expanding the collaboration toward a larger head and neck cell atlas. We'll share more as the next phase takes shape. Read the full article here: https://lnkd.in/eZMFqzvX #ImmunoTherapy #SingleCell #HeadAndNeckCancer #AACR2026

Last week, we joined BIO International Convention 2026 in San Diego as part of the French delegation with Business France. Jonathan Baptista and Martina Lubrano di Ricco met with biotech, pharma and innovation teams working across target identification, indication expansion, asset de-risking and disease relevance. A recurring theme in our conversations was the need for stronger biological rationale before making the next target, asset, or indication decision. Teams are not just looking for more data. They need clearer ways to interpret complex cellular biology and connect it to where a therapeutic program should focus next. For us, this is where digital twins of human cell types become valuable: not as another layer of data, but as a way to connect cellular biology to clearer decisions around targets, assets, and indications. Thank you to Business France and to everyone who connected with us during the week. Missed us at BIO? Reach out to continue the conversation! #BIO2026 #BusinessFrance #DrugDiscovery #TechBio

“It doesn’t matter who has the coolest technology, but how we use it to address drug discovery challenges.” That was one of the strongest takeaways from the Johnson & Johnson R&D Symposium in Beerse, where Yann Abraham joined researchers, clinicians and industry leaders for a full-day discussion on Virtual Biology: From Cells to Patients. The discussion moved across scales, but kept coming back to translation. At the patient level, models are being explored for clinical trajectories, trial design and regulatory decision-making. At the tissue and organ level, human in vitro systems are being developed to improve translatability and reduce reliance on animal models. At the cell level, virtual biology is becoming increasingly relevant for target biology, perturbation response and disease-state understanding. For us, the next question is practical: How do we turn multi-scale biological data into models that help teams decide what to test, which targets to prioritize and where disease relevance is strongest? This is the direction we keep building toward with AI-powered digital twins of human cell types. Thank you to Johnson & Johnson for hosting such a strong discussion on the future of virtual biology! #VirtualBiology #DrugDiscovery #TechBio

We’re heading to Munich! Vrouyr Bilemjian, PhD will be in Munich on 30 June and 1 July, connecting with biotech, AI and life science innovation teams from Bavaria and across Europe. DeepLife’s AI-powered digital twins of human cell types support the decisions that shape therapeutic pipelines: which targets to pursue, where disease relevance is strongest and which indications deserve a closer look. For teams exploring new targets, new indication opportunities or stronger biological rationale for their pipeline, BayOConnect is a good moment to start the conversation. Connect with Vrouyr ahead of the event. See you there! BioM Biotech Cluster Development GmbH #BayOConnect #TechBio #DrugDiscovery

We were excited to join the spaXio DN Kick-Off Meeting in Salzburg, Austria. Our Head of Drug Discovery, Yann Abraham, attended on behalf of the team, joining doctoral candidates, academic partners and industry collaborators from across Europe for the official launch of the MSCA Doctoral Network spaXio. The meeting brought together scientific talks, training activities, networking and discussions across spatial biology, cancer research and computational modelling. For us, spaXio is an important research community to be part of. Understanding metastatic niches depends on more than cell states alone. It also requires spatial context, tissue organisation and the cell-cell interactions that shape how disease develops and progresses. The kick-off was a valuable opportunity to align on the consortium’s scientific direction and explore how AI-enabled biological modelling can contribute to a deeper understanding of metastatic environments. We’re looking forward to the work ahead and to collaborating with the spaXio community! #SpatialBiology #DigitalTwins #CancerResearch

A strong few weeks connecting with the biotech, TechBio, and life sciences ecosystem. At bio:cap in Berlin, we had the opportunity to show how our platform can support target identification, indication expansion, disease relevance assessment, and earlier asset decision-making. It was a valuable setting to discuss practical questions with biotech, pharma, investor, and innovation teams: where this biology matters, which indications deserve attention, and how to make complex cellular data more useful for R&D decisions. The AWS for Healthcare & Life Sciences symposium brought another important angle: how cloud infrastructure, scalable compute, and joint efforts can support the next generation of AI-enabled biology workflows. Both events pointed to the same central insight: better therapeutic decisions cannot be achieved by accumulating more data alone. What's needed is biological context, models that can be understood and interrogated, and workflows that translate scientific knowledge into meaningful R&D choices. Thank you to everyone who stopped by, joined a demo, connected with our team, or continued the conversation after the events! #TechBio #DrugDiscovery #AI

How can we make target discovery more reliable, interpretable, and biologically grounded? Over the past few weeks, our team has joined two strong scientific communities: AI x BIO and Single Cell Biology. At AI x BIO, our poster focused on: “TwinCell: Large Causal Cell Model for Reliable and Interpretable Therapeutic Target Prioritisation” The work illustrates how causal virtual cells and benchmarking through TwinBench can support increasingly interpretable target prioritisation. At Single Cell Biology, our poster focused on: “Niche-Aware Target Discovery by Extending a Single-Cell Platform with Spatial Context” The key idea is that target relevance is not only about which genes are active in addition to about where those signals matter in the tissue. Spatial context can help move single-cell analysis toward more disease-relevant and niche-aware target discovery. Together, these conversations reinforced an important direction for the field: better therapeutic decisions need models that connect cell states, disease mechanisms, and tissue context in ways scientists can understand and act on. Thank you to everyone who visited our posters, asked questions, and connected with our team! #SingleCell #TargetDiscovery #ComputationalBiology

We are proud to share that DeepLife has been selected as one of the 28 new laureates of the “Pionniers de l’IA” call, a France 2030 initiative operated by Bpifrance and announced at VivaTech. Our selected project, ONCODECIDE, focuses on head and neck cancer. Despite advances in treatment, nearly 3 out of 4 oral cancer patients are diagnosed beyond the early stage. As a result, survival drops from almost 90% for localized tumors to nearly one-third for metastatic disease, and the risk of relapse remains high. More precise biological understanding can support earlier detection and better treatment decisions. With ONCODECIDE, we aim to apply DeepLife’s virtual cell models, including TwinCell, to patient-relevant oncology questions. The project will connect prospective clinical studies, high-quality omics data, and cellular disease modelling to support precision medicine in oral cancer. This work will be carried out with our partner Centre Léon Bérard and Prof. Saintigny Pierre. It builds on our existing collaboration around the Oral Mucosa Cell Atlas, which maps cellular changes from healthy tissue to oral cancer and helps deepen our understanding of disease progression. FR version below / Version française ci-dessous Nous sommes fiers d’annoncer que DeepLife fait partie des 28 nouveaux lauréats de l’appel à projets « Pionniers de l’IA », une initiative de France 2030 opérée par Bpifrance et annoncée à l’occasion de VivaTech. Malgré les progrès réalisés dans les traitements, près de 3 patients sur 4 atteints sont encore diagnostiqués à un stade avancé de la maladie. Les conséquences sont majeures : le taux de survie à cinq ans passe d’environ 90 % lorsque la tumeur est localisée à près de 30 % en présence de métastases, tandis que le risque de rechute demeure élevé. Une compréhension plus fine des mécanismes biologiques de la maladie est essentielle pour favoriser un diagnostic plus précoce et améliorer la prise de décision thérapeutique. Avec ONCODECIDE, nous mettrons à profit les modèles de cellules virtuelles développés par DeepLife, notamment TwinCell, pour répondre à des problématiques concrètes en oncologie. Le projet associera des études cliniques prospectives, des données omiques de haute qualité et des modèles cellulaires de la maladie afin de soutenir le développement d’une médecine de précision pour les patients. Ce travail sera mené en collaboration avec le Centre Léon Bérard et le Prof Pierre Saintigny, est dans la continuité de notre collaboration autour de l’Oral Mucosa Cell Atlas, un atlas cellulaire qui cartographie les transformations des tissus dans la maladie. Nous remercions chaleureusement Bpifrance et France 2030 pour leur confiance, ainsi que le Centre Léon Bérard et le Professeur Pierre Saintigny pour ce partenariat que nous sommes enthousiastes à poursuivre. Nous avons hâte de partager avec vous les prochaines étapes de cette aventure.

We’re heading to VIB Training & Conferences Spatial Omics 2026 in Bruges. Our colleague Yann Abraham will present a poster on how spatial context can support more precise, disease-relevant target discovery. Spatial omics is helping researchers move beyond cell identity alone and understand where biology happens in tissue, how cells interact in their native environment, and how these patterns can shape disease progression and treatment response. For us, this is exactly where single-cell biology, spatial context and causal AI become especially powerful. If you’re attending, come and meet Yann at the poster session. We’d be happy to connect and discuss how spatial and single-cell data can inform target prioritisation and disease biology. #SpatialBiology #SingleCell #ComputationalBiology